Full Press Release Details
| Corporate Relationship Department | National Stock Exchange of India Ltd. |
| BSE Limited | "Exchange Plaza" |
| Dalal Street, Fort | Bandra-Kurla Complex, Bandra (East), |
| Mumbai - 400 001 | Mumbai - 400 051 |
| Fax Nos.: 022-22723121 / 22723719 / | Fax Nos.: 022-26598120/ 26598237/ |
| 22722037 / 22722039 | 26598238 |
| Scrip Code: 500124 | Scrip Code: DRREDDY-EQ |
Please find enclosed a Press Release on
"Dr. Reddy's to release Q1 FY 21 results on July 29th, 2020 Earnings call slated for July 29th @ 5:30 PM IST / 8:00 AM
This is for your information.
| /s/ Sandeep Poddar | |
| Sandeep Poddar | |
| Company Secretary |
CC:- New York Stock Exchange Inc.(Stock Code :RDY)
| CONTACT | ||
| DR. REDDY'S LABORATORIES LTD. | Investor relationS | Media relationS |
| 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034, Telangana, India. | AMIT AGARWAL amita@drreddys.com (Ph: +91-40-49002135) | APARNA TEKURI aparnatekuri@drreddys.com (Ph: +91-40- 49002446) |
Dr. Reddy's to release Q1 FY 21 results
Earnings call slated for July 29th
@ 5:30 PM IST / 8:00 AM EDT
India, July 20, 2020
Dr. Reddy's Laboratories Ltd. (BSE: 500124,
NSE: DRREDDY, NYSE: RDY) will announce results for the first quarter ended June 30, 2020 on Wednesday, July 29th, 2020
after the Board Meeting.
| Event | Date and Time | Medium | ||
| Release of financial results | July 29 th , after the Board Meeting | Stock Exchange, Media, Company website, Business wire, Email | ||
| Press meet presentation | Will be available on the Company's website | Company's website www.drreddys.com | ||
| Earnings Call | July 29 th , 5:30 PM IST / 8:00 AM EDT | Hosted by the Company (Details below) | ||
| Playback of Earnings Call | After the earnings call till August 6 th , 2020 | Details below | ||
| Transcript of the Earnings call | Will be available on the Company's website | URL available on Company's website, www.drreddys.com |
Following the release, the management of
the Company will host an earnings call to discuss the Company's financial performance. (Dial In and other details given
The play back will be available after the
earnings call, till August 6th, 2020. For play back dial in phone No: +91 22 7194 5757 | +91 22 6663 5757, and Playback
Conference Joining Information
Option 1: Express Join with DiamondPass
Pre-register with the below link and join without waiting for
| Option 2: Join through below Dial-In Numbers | |
| Universal Access Number: | +91 22 6280 1219 +91 22 7115 8120 |
| Local Access Number: Available all over India | +91 70456 71221 |
| International Toll Free Number: | USA: 1 866 746 2133 UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 |
No password/pin number is necessary to
dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.
Dr. Reddy's: Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical
company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical
Services & Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products
and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major
therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy's
operates in markets across the globe. Our Major markets include - USA, India, Russia & CIS countries, and Europe. For
more information, log on to: www.drreddys.com
Disclaimer: This press release may include statements
of future expectations and other forward-looking statements that are based on the management's current views and assumptions
and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially
from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the
words "may", "will", "should", "expects", "plans", "intends", "anticipates",
"believes", "estimates", "predicts", "potential", or "continue" and similar expressions
identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements
due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency
exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity
levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and
in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration
issues, and (vi) the susceptibility of our industry and the markets addressed by our, and our customers', products and services
to economic downturns as a result of natural disasters, epidemics, pandemics or other widespread illness, including coronavirus
(or COVID-19), and (vii) other risks and uncertainties identified in our public filings with the Securities and Exchange Commission,
including those listed under the "Risk Factors" and "Forward-Looking Statements" sections of our Annual Report
on Form 20-F for the year ended March 31, 2020. The company assumes no obligation to update any information contained herein."
The company assumes no obligation to update any information